(IN BRIEF) Novozymes, a global biosolutions company, has reported its first-half 2023 financial results. The company achieved 3% organic sales growth, an EBIT margin of 25% before special items, and a return on invested capital (ROIC) including goodwill of 17% … Read the full press release
Posted in Business, Denmark, Financial, Industrial, Management, News, Pharma & Biotech, Science
Tagged Ester Baiget, Financial, Novozymes
TOP-LINE DATA FROM REMIX-1 AND REMIX-2 STUDIES DEMONSTRATE SIGNIFICANT SYMPTOM IMPROVEMENT (IN BRIEF) Novartis has unveiled promising results from Phase III trials for remibrutinib, a potent Bruton’s tyrosine kinase (BTK) inhibitor, targeting chronic spontaneous urticaria (CSU). The REMIX-1 and REMIX-2 … Read the full press release
(IN BRIEF) Researchers at the Technical University of Munich (TUM) have developed an inhalable RNA-based drug that targets macrophages, overactive immune cells often responsible for lung damage in diseases like Covid-19. The drug, RCS-21, inhibits the activity of microRNA 21, … Read the full press release
Posted in Business, Education, Germany, Healthcare, Industrial, Management, News, Pharma & Biotech, Science
Tagged Christina Beck, Inhalable, macrophages, medicine, microRNA 21, pneumonia, RCS-21, RNA Drug, RNATICS, Severe Lung Inflammation, Stefan Engelhardt, Technical University of Munich, trimannose, wellness
(IN BRIEF) Novo Nordisk, a global healthcare company, has reported the headline findings from the SELECT cardiovascular outcomes trial. This double-blinded study assessed the impact of subcutaneous once-weekly semaglutide 2.4 mg in comparison to placebo as an adjunct to standard … Read the full press release
Posted in Business, Denmark, Healthcare, Industrial, Management, News, Pharma & Biotech, Science
Tagged Cardiovascular risk, Martin Holst Lange, Novo Nordisk, Obese Adults, overweight, SELECT Trial, Semaglutide 2.4 mg, Wegovy, wellness
(IN BRIEF) BioNTech reported its second-quarter 2023 financial results and corporate update, highlighting significant pipeline advancements in oncology with the initiation of BNT316/ONC-392 Phase 3 pivotal trial and positive data updates across multiple technology platforms. The company also prepares for … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Management, News, Pharma & Biotech, Science
Tagged BioNTech, Financial, Jens Holstein, Omicron-Adapted COVID-19 Vaccine, oncology pipeline, partnership, Pfizer, Prof. Ugur Sahin
(IN BRIEF) Skanska has secured a contract with Seagen to build a 25,000 square meter biomanufacturing facility in Everett, Washington, USA. The facility will encompass manufacturing, storage, shipping, office, and café spaces. The contract is valued at USD 215 million … Read the full press release
Posted in Business, Construction, Financial, Industrial, Infrastructure & Utilities, Investment, Management, News, Pharma & Biotech, Sweden
Tagged Biomanufacturing Facility, partnership, Seagen, Skanska, USA, Washington
(IN BRIEF) BlueRock Therapeutics and bit.bio have announced a collaboration and option agreement to discover and manufacture iPSC-derived regulatory T cells (Tregs) for therapeutic use. Tregs are crucial for immune system balance and controlling excessive immune reactions, making them potential … Read the full press release
Posted in Business, Education, Germany, Healthcare, Management, News, Pharma & Biotech, Science
Tagged Autoimmune Disorders, Bayer, bit.bio, bit.bio’s opti-ox™, BlueRock Therapeutics, iPSC, Mark Kotter, partnership, Stefan Irion, T Cell Therapies, Tregs
(IN BRIEF) Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company owned by Bayer AG, has begun the Phase 1/Phase 2 LION-CS101 clinical trial for patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The trial is evaluating AB-1003 (LION-101), an investigational … Read the full press release
(IN BRIEF) BioNTech SE has completed the acquisition of InstaDeep Ltd., a prominent AI and ML technology company. The acquisition is part of BioNTech’s strategy to enhance AI-driven drug discovery and develop advanced immunotherapies and vaccines for diseases with significant … Read the full press release
(IN BRIEF) Dr. Sariqa Wagley, a microbiologist at the University of Exeter, has been awarded a £676,580 NERC Independent Research Fellowship to investigate dormant bacteria causing cholera and gastroenteric outbreaks. The research will focus on Vibrio species, responsible for human … Read the full press release
(IN BRIEF) AWAKE, a plasma accelerator at CERN, is gearing up for its second phase of data taking with an upgraded plasma source. The accelerator utilizes plasma wakefield acceleration, a novel method that accelerates particles by riding on waves created … Read the full press release
Posted in Business, Industrial, Management, News, Pharma & Biotech, Science, Switzerland
Tagged Alban Sublet, AWAKE Accelerator, CERN, Edda Gschwendtner, Plasma Source, plasma wakefield
(IN BRIEF) Roche and Alnylam have entered into a partnership to jointly develop and commercialize zilebesiran, an investigational RNAi therapeutic for the treatment of hypertension. Hypertension affects a significant number of adults worldwide and is a major risk factor for … Read the full press release
Posted in Business, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Switzerland
Tagged Alnylam, Hypertension Treatment, partnership, RNAi Therapy, Roche, Teresa Graham, Yvonne Greenstreet MBChB, zilebesiran
(IN BRIEF) QIAGEN has launched the QIAseq Normalizer Kits, a new solution for researchers to efficiently pool different DNA libraries for optimal results in next-generation sequencing (NGS) runs. The kit accelerates the process of normalizing DNA concentrations across libraries, reducing … Read the full press release
(IN BRIEF) H. Lundbeck A/S has announced the initiation of CEO succession, with Deborah Dunsire choosing to retire from her role as President and CEO. Charl van Zyl has been appointed as the new President and CEO, and Dunsire will … Read the full press release
Posted in Business, Denmark, Healthcare, Management, Pharma & Biotech
Tagged appointment, biopharma, Board of Directors, CEO, Charl van Zyl, CNS, Deborah Dunsire, Eli Lilly, H. Lundbeck A/S, immunology, Lars Rasmussen, Lundbeck, Neurology, Novartis
(IN BRIEF) Chr. Hansen has received approval from the EU for their 6’-SL HMO, the final addition to their MyOli™ 5 HMO Mix. This authorization allows the highest use level of 6’-SL in infant formula and follow-on formula in the … Read the full press release
(IN BRIEF) Newcastle University researchers, Professor Akane Kawamura and Dr James Dawson, have been awarded prestigious prizes by the Royal Society of Chemistry. Professor Kawamura received the Jeremy Knowles Award for her innovative work in developing technologies and chemical probes … Read the full press release
Posted in Awards, Education, Energy, Gas & Oil, Pharma & Biotech, Science, Technology, United Kingdom
Tagged chemical sciences, chemistry, Dr Helen Pain, Dr James Dawson, Harrison-Meldola Memorial Prize, Jeremy Knowles Award, Newcastle University, Professor Akane Kawamura, Royal Society of Chemistry Prizes
(IN BRIEF) AstraZeneca’s new drug application (NDA) for capivasertib, in combination with Faslodex, has been accepted and granted Priority Review by the US FDA for the treatment of advanced breast cancer. The NDA is being reviewed under Project Orbis, which … Read the full press release
Posted in Healthcare, Pharma & Biotech, United Kingdom
Tagged 2022 San Antonio Breast Cancer Symposium, AstraZeneca, breast cancer, CAPItello-291 Phase III, capivasertib, CDK4/6 inhibitors, endocrine therapies, Faslodex, FDA, Food and Drug Administration, fulvestran, hormone receptor, metastatic breast cancer, NDA, New Drug Application, Priority Review, Susan Galbraith, The New England Journal of Medicine
(IN BRIEF) AstraZeneca and Quell Therapeutics have announced a collaboration to develop innovative treatments for Type 1 Diabetes and Inflammatory Bowel Disease. Quell’s T-regulatory cell engineering technology will be used to create potential curative therapies. AstraZeneca has the option to … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, United Kingdom
Tagged AstraZeneca, autoimmune disease, cell therapies, Foxp3 Phenotype Lock, Iain McGill, IBD, IND, inflammatory bowel disease, Investigational New Drug, Mene Pangalos, multi-modular Treg cell therapy, Quell, Quell Therapeutics, T-regulator, T-regulatory cell engineering, T1D, Treg, type 1 diabetes
(IN BRIEF) Novo Nordisk A/S is in exclusive negotiations to acquire a controlling stake in BIOCORP Production SA, a French company specializing in medical device design and manufacturing. The acquisition would be followed by a mandatory tender offer for all … Read the full press release
(IN BRIEF) According to an independent report, the cost of prescription medicines to the NHS in England reached a record high of £17.2 billion in the financial year 2021-2022. The report reveals that NHS spending on branded medicines has been … Read the full press release
Posted in Education, Government, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Beth Woods, cancer drugs, cost of prescription medicines, COVID-19 vaccines, Dr Huseyin Naci, Dr James Lomas, e Voluntary Scheme for Branded Medicines Pricing and Access, immunosuppression, London School of Economics and Political Science, London School of Hygiene & Tropical Medicine, LSE, LSHTM, malignant disease, medicines, NHS, REPORT, respiratory system disorders, University of York, VPAS
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?